Registry of CytoSorb Therapy in COVID-19 ICU Patients

Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY): Registry of Patient-level Clinical Data on CytoSorb Hemoadsorption Provided Via Integration of the CytoSorb Device Into Extracorporeal Membrane Oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), or Hemoperfusion Extracorporeal Circuits in COVID-19 ICU Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04391920

Acronym

CTC REGISTRY

Enrollment

138

Registered

2020-05-18

Start date

2020-08-28

Completion date

2022-01-20

Last updated

2024-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.

Interventions

DEVICECytoSorb 300 mL device

CytoSorb hemoadsorption provided via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits.

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Confirmed COVID-19 2. Provision of CytoSorb therapy per Instructions for Use (IFU) of the CytoSorb device.

Exclusion criteria

1. CytoSorb therapy for diseases other than COVID-19 2. Survival unlikely within 24 hours (for prospectively enrolled patients)

Design outcomes

Primary

Measure	Time frame
ICU mortality	From the date of start of CytoSorb use until the date of ICU discharge or date of death, whichever comes first, assessed up to 1 year

Secondary

Measure	Time frame
Duration of ECMO after start of CytoSorb	From the date of start of CytoSorb use until the date of cessation of ECMO or date of death, which ever comes first, assessed up to 1 year
Duration of mechanical ventilatory support after start of CytoSorb	From the date of start of CytoSorb use until the date of cessation of mechanical ventilatory support or date of death, which ever comes first, assessed up to 1 year
Duration of pharmacologic hemodynamic support after start of CytoSorb	From the date of start of CytoSorb use until the date of cessation of pharmacologic hemodynamic support or date of death, which ever comes first, assessed up to 1 year
Change in serum concentrations of inflammatory biomarkers after start of CytoSorb	From the day before start of CytoSorb use until the day after cessation of CytoSorb use
Change in Pa02/Fi02 ratio after start of CytoSorb	From the day before start of CytoSorb use until the day after cessation of CytoSorb use

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026